



ESMO Virtual Congress 2020 Industry Satellite Symposium

# INTRINSIC AND ACQUIRED RESISTANCE TO EGFR TKIs: NEW THERAPIES ON THE HORIZON

Available on-demand from Monday 14 September 2020 09:00 CEST at the ESMO Virtual Congress 2020

#### **STEERING COMMITTEE**

Prof. Pilar Garrido, **SPAIN** Dr Marina Garassino, **ITALY** 

## FACULTY

Prof. Benjamin Besse, FRANCE Prof. Lecia Sequist, USA Dr Matthew Krebs, UK Prof. Zosia Piotrowska, USA

#### LEARNING OBJECTIVES

After attending this symposium, participants should be able to:

- Highlight the importance of intrinsic and acquired EGFR resistance mutations in NSCLC and how this can impact patient outcomes
- Understand the increasing role of genetic and molecular profiling and biomarkers in tailoring therapy
- Describe how current and future research in the treatment of NSCLC may drive therapeutic decisions for patients with specific activating and resistance EGFR mutations

This exciting symposium will be pre-recorded, but don't miss out the opportunity to join our live Q&A session on Friday 18 September 15:30-16:00 CEST and ask your questions to the faculty.

### PROGRAM

SESSION	FACULTY
Introduction • An overview of advanced NSCLC: Where are we now? • The evolving treatment landscape in NSCLC	Prof. Pilar Garrido Dr Marina Garassino
Panel discussion: How should we continue treatment following first-line therapy with EGFR TKIs?	All faculty Chaired by Prof. Pilar Garrido
Uncommon EGFR mutations in NSCLC	Dr Matthew Krebs Prof. Zosia Piotrowska
Panel discussion: How should we manage uncommon EGFR mutations?	All faculty Chaired by Dr Marina Garassino
Looking to the future: How can emerging therapeutic options influence the management landscape?	Prof. Benjamin Besse Prof. Lecia Sequist
Key learnings and closing remarks	All faculty Closing from Dr Marina Garassino



With the support of Janssen Pharmaceutical Con of Johnson & Johnson in EMEA Janssen Pharmaceutica NV Turnhoutseweg 30 B-2340 Berss, Belgium Date of preparation: August 2020 FNUT396

